Tempus Announces Expansion Of AI-Enabled Care Pathway Intelligence Platform Into Breast Cancer

Tempus Next supports providers in closing gaps in care for eligible patients based on clinical guidelines.

Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of its care pathway intelligence platform, Tempus Next, into breast cancer. Since its launch in 2024, Tempus Next has screened thousands of patients across its network of provider sites, helping close critical care gaps for patients with lung cancer. Now, the platform will support five different biomarker testing gaps specific to breast cancer with the goal of helping physicians deliver guideline-directed medical care to eligible patients.

Tempus Next supports physicians administering guideline-based care by surfacing care gaps and identifying patients who may benefit from these guideline-based suggestions. The platform integrates multimodal data available in the patient's electronic medical record (EMR) with up-to-date clinical guidelines to support providers in delivering guideline-based care. As with lung cancer, clinical guidelines around breast cancer are continually evolving, and Tempus is working to help providers keep pace, starting at Mercy, which has already integrated Tempus Next for both breast and lung cancer into its EMR system to support patient care. Mercy has over 1,000 physician practice locations and outpatient facilities, more than 5,000 physicians and advanced practitioners serving patients across Arkansas, Illinois, Kansas, Missouri and Oklahoma.

"Staying current with rapidly evolving clinical guidelines—especially regarding biomarker testing like ESR1 mutations in metastatic breast cancer—remains a challenge for healthcare providers everywhere," Dr. Jay Carlson, DO, Medical Director of Oncology and Clinical Chair of Mercy Research. "Tools like Tempus Next support our team in identifying patients who may benefit from guideline-recommended testing, helping us deliver truly personalized cancer care."

"Keeping up with the complex and rapidly evolving clinical guidelines is a nearly impossible task for physicians, especially those in the community setting that are serving so many patients a day," said Chris Scotto DiVetta, Senior Vice President of AI Applications at Tempus. "We believe it is critical to partner with these providers, such as Mercy, to meet them where they are and design custom integrations that make it easier for their team to deliver optimized care."

The development of Tempus Next, including its breast cancer module, was funded by Tempus and one or more life sciences company sponsors.